This study is creating a collection of blood samples (a biorepository) from patients undergoing plasma exchange (PLEX) procedures. PLEX is a standard treatment for immune-mediated diseases like Antibody-mediated Rejection, NMO Spectrum Disorder, TTP, and CIDP, where it removes harmful substances, often antibodies, from the blood. You can join if you are between 12 and 99 years old and are receiving PLEX. This study will not change your treatment plan. Researchers will measure IgG and IgM antibody levels over 1-2 weeks to understand how PLEX affects them. The goal is to collect samples for current and future research to learn more about these conditions and treatments. The study aims to enroll 200 participants, but its current status is unclear.

Study design

This is an observational study, meaning researchers will collect information without influencing your treatment. It plans to enroll 200 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Researchers will measure antibody levels over the course of treatment, typically 1-2 weeks.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.